国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2011年
8期
630-636
,共7页
非小细胞肺癌%表皮生长因子受体酪氨酸激酶抑制剂%获得性耐药%T790M突变%MET扩增
非小細胞肺癌%錶皮生長因子受體酪氨痠激酶抑製劑%穫得性耐藥%T790M突變%MET擴增
비소세포폐암%표피생장인자수체락안산격매억제제%획득성내약%T790M돌변%MET확증
Non-small cell lung cancer%Epidermal growth factor receptor-tyrosine kinase inhibitor%Acquired resistance%T790M mutation%MET amplification
表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌的治疗中发挥了重要作用,但开始对此药敏感的患者经过6～12个月的治疗后多数会出现获得性耐药,成为其持续用药难以回避的治疗瓶颈.本文主要阐述T790M突变和MET扩增等非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的机制及逆转耐药的新一代酪氨酸激酶抑制剂和其他靶向治疗药物的研究进展.
錶皮生長因子受體酪氨痠激酶抑製劑在非小細胞肺癌的治療中髮揮瞭重要作用,但開始對此藥敏感的患者經過6～12箇月的治療後多數會齣現穫得性耐藥,成為其持續用藥難以迴避的治療瓶頸.本文主要闡述T790M突變和MET擴增等非小細胞肺癌對錶皮生長因子受體酪氨痠激酶抑製劑穫得性耐藥的機製及逆轉耐藥的新一代酪氨痠激酶抑製劑和其他靶嚮治療藥物的研究進展.
표피생장인자수체락안산격매억제제재비소세포폐암적치료중발휘료중요작용,단개시대차약민감적환자경과6～12개월적치료후다수회출현획득성내약,성위기지속용약난이회피적치료병경.본문주요천술T790M돌변화MET확증등비소세포폐암대표피생장인자수체락안산격매억제제획득성내약적궤제급역전내약적신일대락안산격매억제제화기타파향치료약물적연구진전.
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) plays an important role in the treatment of non-small cell lung cancer. However,after EGFR-TKI therapy for six to twelve months, acquired resistance may occur in patients who are initially sensitive to it, which blocks the sustained medication. This article mainly reviews the mechanism of acquired resistance of non-small cell lung cancer to EGFR-TKI including T790M mutation and MET amplification and the progress on new generation tyrosine kinase inhibitor and other targeted agents.
